AI assistant
BELLUSCURA PLC Board/Management Information 2021
7514_mang_2021-06-15_58351792-e592-4ea7-b04e-cbff6c25737c.html
Board/Management Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 8643B
Belluscura PLC
15 June 2021
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Belluscura PLC
("Belluscura" or the "Company" or "Group")
Senior Management Appointment
Keith Cook appointed as Vice-President of Operations
LONDON, U.K. AND PLANO, TX, U.S. (15 June 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces the appointment of Keith Cook as Vice President of Operations based in Plano, Texas. Prior to joining Belluscura, Keith worked as Director of Operations at Inogen, a major provider of oxygen concentrators, and was instrumental in spearheading a team that led the rapid growth in production volume needed to support a 100% increase in revenue over four years from 2015-2019. Keith will be a key member of the Executive team and will be integral in leading the manufacturing team in preparation for the launch of the X-PLO2R portable oxygen concentrator in Q3 of this year.
Robert Rauker, CEO of Belluscura plc, said: "We are delighted to have Keith join the Belluscura team. His significant experience in the manufacturing of oxygen enrichment devices will help drive the successful launch of the X-PLO2R family of oxygen concentrators."
For further information please contact:
| Belluscura plc | www.belluscura.com |
| Robert Rauker, Chief Executive Officer | via Walbrook PR |
| Anthony Dyer, Chief Financial Officer | |
| SPARK Advisory Partners Limited (NOMAD) | Tel: +44 (0)20 3368 3550 |
| Neil Baldwin | |
| Dowgate Capital Limited (Broker) | Tel: +44 (0)20 3903 7715 |
| James Serjeant / Nicholas Chambers | |
| Walbrook PR Ltd (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or [email protected] |
| Paul McManus / Sam Allen | Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 |
About Belluscura plc (www.belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
Belluscura is listed on the AIM market of the London Stock Exchange (AIM: BELL).
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOASFUFULEFSEDM